Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability

Journal of Affective Disorders

Volumn 58, Issue 1, 2000, Pages 19-36

  Anderson, Ian M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Depression; Meta analysis; SSRIs; Systematic review; TCAs

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; NOMIFENSINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

EID: 0034177434     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(99)00092-0     Document Type: Article

References (155)

1. Altamura A.C., Percudani M., Guercetti G., Invernizzi G. Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitriptyline. Int. Clin. Psychopharmacol. 4:1989;103-106.
2. Amin M.M., Ananth J.V., Coleman B.S., Darcourt G., Farkas T., Goldstein B., Lapierre Y.D., Paykel E., Wakelin J.S. Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study. Clin. Neuropharmacol. 7:(Suppl. 1):1984;S316-S317.
3. Amore M., Bellini M., Berardi D., Berlinzani L., Cervino G., Cremonini A., Ferrari G., Innamorati A. Double-blind comparison of fluvoxamine and imipramine in depressed patients. Curr. Ther. Res. 46:1989;815-820.
4. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 8:1994;238-249.
5. Anderson I.M., Tomenson B.M. Treatment discontinuation with selective serotonin reuptake inhibitors compared to tricyclic antidepressants: a meta-analysis. Br. Med. J. 310:1995;1433-1438.
6. Anderson I.M. SSRIs versus tricyclic antidepressants in depressed in-patients: a meta-analysis of efficacy and tolerability. Depress. Anxiety. 7:(Suppl. 1):1998;11-17.
7. Anderson I.M. A meta-analysis of controlled trials comparing SSRIs in the treatment of depression. J. Psychopharmacol. 12:(Suppl A):1998;A20.
8. Arminen S.-L., Ikonen U., Pulkkinen M., Leinonen E., Mahlanen A., Koponen H., Kourula K., Ryyppo J., Lehtonen M.-L., Vartiainen H., Lehtinen V., Tamminen T. Paroxetine and imipramine: a 12 week, double-blind multicentre study in hospitalized depressed patients. Nord. J. Psychiatry. 46:(Suppl. 27):1992;27-31.
9. Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr. Scand. 80:1989;141-142.
10. Battegay R., Hager M., Rauchfleisch U. Double-blind comparative study of paroxetine and amitriptyline in depressed patients of a university psychiatric out-patient clinic (pilot study). Neuropsychobiology. 13:1985;31-37.
11. Beasley C.M. Jr., Sayler M.E., Potvin J.H. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int. Clin. Psychopharmacol. 8:1993;143-149.
12. Bersani G., Rapisarda V., Ciani N., Bertolino A., Sorge G. A double-blind comparative study of sertraline and amitriptyline in outpatients with major depressive episodes. Hum. Psychopharmacol. 9:1994;63-68.
13. Bignamini A., Rapisarda V. A double-blind multicentre study of paroxetine and amitriptyline in depressed out-patients. Int. Clin. Psychopharmacol. 6:1992;37-41.
14. Blashki T.G., Mowbray R., Davies B. Controlled trial of amitriptyline in general practice. Br. Med. J. 1:1971;133-138.
15. Bouchard J.M., Delaunay J., Delisle J.-P., Grassel N., Mermberg P.F., Molczadzki M., Pagot R., Richou H., Robert G., Ropert R., Schuller E., Verdeau-Pailles J., Zarifan E., Hopfner Petersen H.E. Citalopram versus maprotiline: A controlled, clinical multicentre trial in depressed patients. Acta Psychiatr. Scand. 76:1987;583-592.
16. Bourin, M., 1990. A double-blind comparison of paroxetine and clomipramine in depressed outpatients. Presented at the 17th CINP Kyoto, Japan.
17. Bowden C.L., Schatzberg A.F., Rosenbaum A., Contreras S.A., Samson J.A., Dessain E., Sayler M. Fluoxetine and desipramine in major depressive disorder. J. Clin. Psychopharmacol. 13:1993;305-310.
18. Bramanti P., Ricci R.M., Roncari R., Bilone F., Inga F., Teti V., DeCristofaro A.M., Ceccarelli G., DiPerri R., Candela L. An Italian multicentre experience with fluvoxamine, a new antidepressant drug, versus imipramine. Curr. Ther. Res. 43:1988;718-724.
19. Bremner J.D. Fluoxetine in depressed patients: A comparison with imipramine. J. Clin. Psychiatr. 45:1984;414-419.
20. Bressa G.M., Brugnoli R., Pancheri P. A double-blind study of fluoxetine and imipramine in major depression. Int. Clin. Psychopharmacol. 4:1989;69-73.
21. Byrne M.M. Meta-analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta Psychiatr. Scand. 80:1989;138-139.
22. Chouinard G. A double blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of out-patients with major depressive disorder. J. Clin. Psychiatry. 46:1985;32-37.
23. Christiansen P.E., Behnke K., Black C.H., Öhrström J.K., Bork-Rasmussen H., Nilsson J. Paroxetine and amitriptyline in the treatment of depression in general practice. Acta. Psychiatr. Scand. 93:1996;158-163.
24. Claghorn J.L., Earl C.Q., Walczak D.D., Stoner K.A., Wong L.F., Kanter D., Houser V.P. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J. Clin. Psychopharmacol. 16:1996;113-120.
25. Cohn C.K., Shrivastava R., Mendels J., Cohn J.B., Fabre L.F., Claghorn J.L., Dessain E.C., Itil T.M., Lautin A. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J. Clin. Psychiatr. 51:1990;28-33.
26. Cohn J.B., Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with depressive disorder. J. Clin. Psychiatr. 46:1985;26-31.
27. Corne S.J., Hall J.R. A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice. Int. Clin. Psychopharmacol. 4:1989;245-254.
28. Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 114:1994;559-565.
29. Danish University Antidepressant Group . Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 90:1986;131-138.
30. Danish University Antidepressant Group . Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicentre study. J. Affect. Disord. 18:1990;289-299.
31. de Jonghe F., Ravelli D.P., Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry. 24:1991;62-67.
32. de Jonghe F., Swinkels J., Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry. 21:1991;21-27.
33. De Wilde J.E.M., Doogan D.P. Fluvoxamine and clomipramine in endogenous depression. J. Affect. Disord. 4:1982;249-259.
34. De Wilde J.E., Mertens C., Wakelin J.S. Clinical trials of fluvoxamine vs clomipramine with single and three times daily dosing. Br. J. Clin. Pharmacol. 15:1983;427S-431S.
35. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trial. 7:1986;177-188.
36. Dick P., Ferrero E. A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine. Br. J. Clin. Pharmacol. 15:1983;419S-425S.
37. Dominguez R.A., Goldstein B.J., Jacobson A.F., Steinbook R.M. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J. Clin. Psychiatr. 46:1985;84-87.
38. Donoghue J., Tylee A., Wildgust H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom. Br. Med. J. 313:1996;861-862.
39. Doogan D.P., Langdon C.J. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int. Clin. Psychopharmacol. 9:1994;95-100.
40. Dowling B., Webb M.G.T., Halpin C.M., Sangiwa M.G.H. Fluoxetine: a comparative study with dothiepin. Irish J. Psychiatry. Spring:1990;3-7.
41. Dunbar G.C., Cohn J.B., Fabre L.F., Feighner J.P., Fieve R.R., Mendels J., Shrivastava R.K. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br. J. Psychiatr. 159:1991;394-398.
42. Dunbar G.C. Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology. 51:1995;137-144.
43. Dunner D.L., Cohn J.B., Walshe T., Cohn C.K., Feighner J.P., Rieve R.R., Halikas J.P., Hartford J.T., Hearst E.D., Settle E.C., Menolascino F.J., Muller D.J. Two combined, multicentre double-blind studies or paroxetine and doxepin in geriatric patients with major depression. J. Clin. Psychiatr. 53:1992;57-60.
44. Dunner D.L. An overview of paroxetine in the elderly. Gerontology. 40:1994;21-27.
45. Effective Health Care . The treatment of depression in primary care. Effective Health Care Bull. 5:1993;1-12.
46. Egger M., DaveySmith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br.Med.J. 315:1997;629-634.
47. Fabre L.F., Scharf M.B., Itil T.M. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: A clinical study. J. Clin. Psychiatr. 52:1991;62-67.
48. Fabre L., Birkhimer L.J., Zaborny B.A., Wong L.F., Kapik B.M. Fluvoxamine versus imipramine and placebo: a double blind comparison in depressed patients. Int. Clin Psychopharmacol. 11:1996;119-127.
49. Fairweather D.B., Kerr J.S., Harrison D.A., Moon C.A., Hindmarch I. A double-blind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients. Hum. Psychopharmacol. 8:1993;41-47.
50. Fawcett J., Zajecka J.M., Kravitz H.M., Edwards J., Jeffriess H., Scorza E. Fluoxetine versus amitriptyline in adult out-patients with major depression. Curr. Ther. Res. 45:1989;821-832.
51. Feighner J.P. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J. Clin. Psychiatr. 46:1985;369-372.
52. Feighner J.P., Robins E., Guse S.B., Woodruff R.A., Winokur G., Munos R. Diagnostic criteria for use in psychiatric research. Arch. Gen. Psychiatr. 26:1972;57-63.
53. Feighner J.P., Boyer W.F., Merideth C.H., Hendrickson G.G. A double-blind comparison of fluoxetine, imipramine and placebo in out-patients with major depression. Int. Clin. Psychopharmacol. 4:1989;127-134.
54. Feighner J.P., Boyer W.F., Meredith C.H., Hendrickson G.G. A placebo-controlled in-patient comparison of fluvoxamine maleate and imipramine in major depression. Int. Clin. Psychopharmacol. 4:1989;239-244.
55. Feighner J.P., Cohn J.B. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J. Clin. Psychiatr. 46:1985;20-25.
56. Fontaine R. The efficacy and safety of sertraline versus imipramine in out-patients with major depression: a six month double-blind, parallel multicenter study. Eur. Neuropsychopharmacol. 1:1991;P75.
57. Gagiano C.A., Muller P.G.M., Fourie J., LeRoux J.F. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients. Acta. Psychiatr. Scand. 80:1989;130-131.
58. Gasperini M., Gatti F., Bellini L., Anniverno R., Smeraldi E. Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine: a double-blind study in depressed in-patients. Pharmacopsychiatry. 26:1992;186-192.
59. Geretsegger C., Stuppaeck C.H., Mair M., Platz T., Fartacek R., Heim M. Multicentre double blind study of paroxetine and amitriptyline in elderly depressed patients. Psychopharmacology. 119:1995;277-281.
60. Ginestet D., Alby J.M., Besancon G., Carrier G., Cordier B., Degiovanni A., Dufour H., Ferreri M., Leger L., Moron P., Pellet J., Perivier E., Singer L., Ulliac G. Fluoxetine in endogenous depression melancholia versus clomipramine. Int. Clin. Psychopharmacol. 4:1989;37-40.
61. Gonella G., Baignoli G., Ecari U. Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study. Curr. Med. Res. Opin. 12:1990;177-184.
62. Gravem A., Amthor K.F., Astrup C., Elgen K., Gjessing L.R., Gunby B., Pettersen R.D., Kyrdalen L., Vaadal J., Ofsti E., Aarvold A. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr. Scand. 75:1987;478-486.
63. Gøtzsche P.C. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control. Clin. Trials. 10:1989;31-56.
64. Grimsley S.R., Jann M.W. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin. Pharm. 11:1992;930-956.
65. Guelfi J.D., Dreyfus J.F., Pichot P., G.E.P.E.C.E.P. A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br. J. Clin. Pharmacol. 15:1983;411S-417S.
66. Guilibert E., Pélicier Y., Archambault J.C., Chabannes J.P., Clerc G., Desvilles M., Guibert M., Pagot R., Poisat J.L., Thobie Y. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr. Scand. 80:1989;132-134.
67. Guy W., Wilson W.H., Ban T.A., King D.L., Manov G., Fjetland I.K. Double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacol. Bull. 20:1984;73-78.
68. Hale A.S. The importance of accidents in evaluating the cost of SSRIs: a review. Int. Clin. Psychopharmacol. 9:1994;195-201.
69. Harris B., Szulecka T.K., Anstee J.A. Fluvoxamine versus amitriptyline in depressed hospital out-patients: A multicentre double-blind comparative trial. Br. J. Clin. Res. 2:1991;89-99.
70. Hedges L.V., Olkin I. Statistical Methods for Meta-Analysis. 1985;Academic Press, Orlando, FL.
71. Heiligenstein J.H., Tollefson G.D., Faries D.E. A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. Int. Clin. Psychopharmacol. 8:1993;247-251.
72. Henry J.A., Alexander C.A., Sener E.K. Relative mortality from overdose of antidepressants. Br. Med. J. 310:1995;221-224.
73. Hotopf M., Lewis G., Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br. J. Psychiatry. 168:1996;404-409.
74. Hotopf M., Hardy R., Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br. J. Psychiatry. 170:1997;120-127.
75. Hutchinson D.R., Tong S., Moon C.A.L., Vince M., Clarke A. A double blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients. Br. J. Clin. Res. 2:1991;43-57.
76. Itil T.M., Shrivastava R.K., Mukherjee S., Coleman B.S., Michael S.T. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br. J. Clin. Pharmacol. 15:1983;433S-438S.
77. Judd F.K., Moore K., Norman T.R., Burrows G.D., Gupta R.K., Parker G. A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Aust NZ J. Psychiatry. 27:1993;49-55.
78. Kasper S., Fuger J., Moller H.-J. Comparative efficacy of antidepressants. Drugs. 43:1992;11-23.
79. Kasper S., Voll G., Vieira A., Kick H. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression - results of a double-blind trial. Pharmacopsychiatry. 23:1990;135-142.
80. Keegan D., Bowen R.C., Blackshaw S., Saleh S., Dayal N., Remillard F., Shrikhande S., Cebrian Perez S., Boulton A., Richardson S., D'Arcy C. A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int. Clin. Psychopharmacol. 6:1991;117-124.
81. Kerkhofs M., Rielaert C., de Maertelaer V., Linkowski P., Czarka M., Mendlewicz J. Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables. Int. Clin. Psychopharmacol. 5:1990;253-260.
82. Klok C.J., Brouwer G.J., VanPraag H.M., Doogan D. Fluvoxamine and clomipramine in depressed patients: A double-blind clinical study. Acta Psychiatr. Scand. 64:1981;1-11.
83. Kuha S., Mehtonen O.-P., Henttonen A., Naarala M. The efficacy of fluoxetine versus maprotiline in depressed patients and by dose. Nord. Psykiatr. Tidsskr. 45:1991;109-117.
84. Kuhs H., Rudolf G.A.E. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr. Scand. 80:1989;145-146.
85. Laakmann G., Blaschke D., Engel R., Schwarz A. Fluoxetine vs. amitriptyline in the treatment of depressed out-patients. Br. J. Psychiatry. 153:1988;64-68.
86. Lader M. Fluoxetine efficacy vs. comparative drugs: an overview. Br. J. Psychiatry. 153:(Suppl. 3):1988;51-58.
87. Lapierre Y.D., Browne M., Horn E., Oyewumi L.K., Sarantidis D., Roberts N., Badoe K., Tessier P. Treatment of major affective disorder with fluvoxamine. J. Clin. Psychiatry. 48:1987;65-68.
88. Laursen L.A., Mikkelsen P.L., Rasmussen S., leFevreHonore P. Paroxetine in the treatment of depression - a randomized comparison with amitriptyline. Acta Psychiatr. Scand. 71:1985;249-255.
89. Lepine, J.P., Wiseman, R., 1996. Treatment of severe major depression: a double-blind study of sertraline and clomipramine. Presented at the June CINP, Melbourne, Australia.
90. Levine S., Deo R., Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Br. J. Psychiatry. 150:1987;653-655.
91. Loeb C., Albano C., Gandolfo C. Fluoxetine versus imipramine. Int. Clin. Psychopharmacol. 4:1989;75-79.
92. Lydiard R.B., Lyle K.L., Morton W.A., Steele T.E., Kellner C., Laraia M.T., Ballenger J.C. Fluvoxamine, imipramine and placebo in the treatment of depressed out-patients: Effects on depression. Psychopharmacol. Bull. 25:1989;68-70.
93. Lydiard, R.B., The Depression Research Group, 1996. Sertraline versus amitriptyline and quality of life: a double-blind placebo-controlled study. Presented at the June CINP, Melbourne, Australia.
94. Mackay F.J., Dunn N.R., Wilton L.V., Pearce G.L., Freemantle S.N., Mann R.D. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol. Drug Safety. 6:1997;235-246.
95. Manna V., Martucci N., Agnoli A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs. clomipramine in the treatment of major depressive disorders. Int. Clin. Psychopharmacol. 4:1989;81-88.
96. March J.S., Kobak K.A., Jefferson J.W., Mazza J., Greist J.H. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in out-patients with major depression. J. Clin. Psychiatr. 51:1990;200-202.
97. Martin R.M., Hilton S.R., Kerry S.M., Richards N.M. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. Br. Med. J. 314:1997;646-651.
98. Masco H.L., Sheetz M.S. Double-blind comparison of fluoxetine and amitriptyline in the treatment of major depressive illness. Adv. Ther. 2:1985;275-283.
99. McEntee, W., Ko, G., Richter, E., Foster, G.V., 1996. Sertraline and nortriptyline: heart rate, cognitive function and quality of life in the depressed elderly. Presented at the 20th CINP, Melbourne, Australia, 23-27 June 1996.
100. Mittmann N., Herrmann N., Einarson T.R., Busto U.E., Lanctot L.L., Liu B.A., Shulman K.I., Silver I.L., Naranjo C.A., Shear N.H. The efficacy, safety and tolerability of antidepressants in late life depression: A meta-analysis. J. Affect. Disord. 46:1997;191-217.
101. Moller H.J., Haug G. Secondary and meta-analysis of the efficacy of non-tricyclic antidepressants. Pharmacopsychiatry. 2:1988;363-364.
102. Moller H.-J., Berzewski H., Eckmann F., Gonzalves N., Kissling W., Knorr W., Ressler P., Rudolf G.A.E., Steinmeyer E.M., Magyar I., Szucs R., Szilard J. Double-blind multicentre trial of paroxetine and amitriptyline in depressed in-patients. Pharmacopsychiatry. 26:1993;75-78.
103. Montgomery S.A., Bebbington P., Cowen P., Deakin W., Freeling P., Hallstrom C., Katona C., King D., Leonard B., Levine S., Phanjoo A., Peet M., Thompson C., Thompson C. Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. J. Psychopharmacol. 7:1993;19-23.
104. Montgomery S.A., Henry J., Macdonald G., Dinan T., Lader M., Hindmarch I., Clare A., Nutt D. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int. Clin. Psychopharmacol. 9:1994;47-53.
105. Moon C., Vince M. Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Br. J. Clin. Pract. 50:1996;240-244.
106. Moon C.A.L., Jago W., Wood K., Doogan D.P. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice. J. Psychopharmacol. 8:1994;171-176.
107. Mullin J.M., Pandita-Gunawardena V.R., Whitehead A.M. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br. J. Clin. Pract. 42:1988;51-55.
108. Nathan R.S., Perel J.M., Pollack B.G., Kupfer D.J. The role of neuropharmacologic selectivity in antidepressant action: Fluvoxamine versus desipramine. J. Clin. Psychiatr. 51:1990;367-372.
109. Nielsen B.M., Behnke K., Arup P., Christiansen P.E., Geisler A., Ipsen E., Maach-Moller B., Ohrberg S.C. A comparison of fluoxetine and imipramine in the treatment of out-patients with major depressive disorder. Acta Psychiatr. Scand. 87:1993;269-272.
110. Nielsen O.A., Mosing I., Petersen J.S., Larsen T., Moller S.E., Manniche P.M., Skausig O.B. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements. Acta Psychiatr. Scand. 84:1991;233-241.
111. Noguera R., Altuna R., Alvarez E., Ayuso J.L., Casais L., Udina C. Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial. J. Affect. Disord. 22:1991;119-124.
112. Norton K.R.W., Sireling L.I., Bhat A.V., Rao B., Paykel E.S. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. J. Affect. Disord. 7:1984;297-308.
113. Øhrberg S., Christiansen P.E., Severin B., Calberg H., Nilakantan B., Borup B., Sogaard A., Larsen J., Loldrup D., Bahr B., Siebuhr N., Gregersen B., Jacobsen F., Liljestrom M., Manniche P.M., Bech P. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr. Scand. 86:1992;437-444.
114. Olfson M., Marcus S.C., Pincus H.A., Zito J.M., Thompson J.W., Zarin D.A. Antidepressant prescribing practices of outpatient psychiatrists. Arch. Gen. Psychiatry. 55:1998;310-316.
115. Ottevanger E.A. The efficacy of fluvoxamine in patients with severe depression. Br. J. Clin. Res. 2:1991;125-132.
116. Ottevanger E.A. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. L'Encephale. 21:1995;317-321.
117. Pakesch G., Dossenbach M. Depressive syndrome in a clinical trial with private practitioners. [German] OT - Wirkung und Sicherheit von Fluoxetin versus Clomipramin bei ambulanten Patienten mit einem depressiven Syndrom in einer klinischen Prufung bei niedergelassenen Arzten. Wien. Klin. Wochenschr. 103:1991;176-182.
118. Pande A.C., Sayler M.E. Fluoxetine - A clinical and research update: Severity of depression and response to fluoxetine. Int. Clin. Psychopharmacol. 8:1993;243-245.
119. Paykel E.S., Priest R.G. Recognition and management of depression in general practice: consensus statement. Br. Med. J. 305:1992;98-202.
120. Pélicier Y., Schaeffer P. Etude multicentrique en double aveugle comparant l'efficacité et la tolerance de la paroxetine et de la clomipramine dans la dépression réactionnelle du sujet âgé L'Encéphale. XIX:1993;257-261.
121. Peters U.H., Lenhard P., Metz M. Therapy of depression in the psychiatrist's office - A double-blind multicenter study. Nervenheilkunde. 9:1990;28-31.
122. Poelinger W., Haber H. Fluoxetine 40 mg vs. maprotiline 75 mg in the treatment of out-patients with depressive disorders. Int. Clin. Psychopharmacol. 4:1989;47-50.
123. Rahman M.K., Akhtar M.J., Savla N.C., Sharma R.R., Kellett J.M., Ashford J.J. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br. J. Clin. Pharmacol. 45:1991;255-258.
124. Ravindran A.V., Judge R., Hunter B.N., Bray J., Morton N.H. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. J. Clin. Psychiatry. 58:1997;112-118.
125. Ravindran A.V., Teehan M.D., Bakish D., Yatham L., O'Reilly R., Fernando M.L., Manchanda R., Charbonneau Y., Buttars J. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum. Psychopharmacol. 10:1995;273-281.
126. Reimherr F.W., Chouinard G., Cohn C.K., Cole J.O., Itil T.M., LaPierre Y.D., Masco H.L., Mendels J. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in out-patients with major depression. J. Clin. Psychiatr. 51:1990;18-27.
127. Remick R.A., Claman J., Reesal R., Gibson R.E., Agbayewa M.O., Lam R.W., Keller F.D. Comparison of fluoxetine and desipramine in depressed outpatients. Curr. Ther. Res. Clin. Exp. 53:1993;457-465.
128. Remick R.A., Keller F.D., Gibson R.E., Carter D. A comparison between fluoxetine and doxepin in depressed patients. Curr. Ther. Res. 46:1989;842-848.
129. Remick R.A., Reesal R., Oakander M., Allen J., Claman J., Ramirez C.E., Perry K., Kelle F.D. Comparison of fluvoxamine and amitriptyline in depressed outpatients. Curr. Ther. Res. Clin. Exp. 55:1994;243-250.
130. Robertson M.M., Abou-Saleh M.T., Harrison D.A., Nairac B.L., Edwards D.R.L., Lock T., Burns R.A., Katona C.L.E. A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness. J. Psychopharmacol. 8:1994;98-103.
131. Ropert R. Fluoxetine versus clomipramine in major depressive disorders. Int. Clin. Psychopharmacol. 4:1989;89-95.
132. Rosenberg C., Damsbo N., Fuglum E., Jacobsen L.V., Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int. Clin. Psychopharmacol. 9:(Suppl 1):1994;41-48.
133. Roth D., Mattes J., Sheehan K.H., Sheehan D.V. A double-blind comparison of fluvoxamine, despiramine and placebo in out-patient with depression. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 14:1990;929-939.
134. Shaw D.M. A comparison of the antidepressant action of citalopram and amitriptyline. Br. J. Psychiatr. 149:1986;515-517.
135. Shillingford, J.S., Hindmarch, I., Clarke, A., Vince, M.J., 1990. A double-blind comparison of paroxetine and dothiepin on efficacy and tolerability in depressed community patients. Presented at the CINP Kyoto, Japan.
136. Song F., Freemantle N., Sheldon T.A., House A., Watson P., Long A., Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br. Med. J. 306:1993;683-687.
137. South Wales Antidepressant Drug Trial Group . A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness. Int. Clin. Psychopharmacol. 3:1988;75-81.
138. Spitzer R., Endicott J., Robins E. Research Diagnostic Criteria. 1975;New York State Psychiatric Institute, New York.
139. Stage K.B., Bech P., Gram L.F., Kragh-Sørensen P., Rosenberg C., Øhrberg S. Are in-patient depressives more often of the melancholic subtype? Acta Psychiatr. Scand. 98:1998;432-436.
140. Staner L., Kerkhofs M., Detroux D., Leyman S., Linkowski P., Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep. 18:1995;470-477.
141. Stark P., Hardison C.D. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in out-patients with major depressive disorder. J. Clin. Psychiatr. 46:1985;53-58.
142. Steffens D.C., Krishnan K.R.R., Helms M.J. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress. Anxiety. 6:1997;10-18.
143. Stott P.C., Blagden M.D., Aitken C.A. Depression and associated anxiety in primary care: a double-blind comparison of paroxetine and amitriptyline. Eur. Neuropsychopharmacol. 3:1993;324-325.
144. Stuppaeck C.H., Geretsegger C., Whitworth A.B., Schubert H., Platz T., Konig P., Hinterhuber H., Fleischhacker W. A multicentre double-blind trial of paroxetine versus amitriptyline in depressed in-patients. J. Clin. Psychopharmacol. 14:1994;241-246.
145. Tamminen T.T.A., Lehtinen V.V. A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. Int. Clin. Psychopharmacol. 4:1989;51-56.
146. Taneri Z., Kohler R. Fluoxetine versus nomifensine in out-patients with neurotic or reactive depression disorder. Int. Clin. Psychopharmacol. 4:1989;56-61.
147. Thompson C. Sertraline in primary care setting. Racagni G., Biological Psychiatry. 1991;863-865 Elsevier.
148. Thompson C., Thompson C.M. The prescribing of antidepressants in general practice. II. A Placebo-controlled trial of low-dose dothiepin. Hum. Psychopharmacol. 4:1989;191-204.
149. Tignol J., Stoker M.J., Dunbar G.C. Paroxetine in the treatment of melancholia and severe depression. Int. Clin. Psychopharmacol. 7:1992;91-94.
150. Timmerman L., De Beurs P., Tan B.K., Leijnse-Ybema H., Sanchez C., Hopfner Petersen H.E., Cohen-Stuart M.H. A double-blind comparative clinical trial of citalopram vs. maprotiline in hospitalized depressed patients. Int. Clin. Psychopharmacol. 2:1987;239-253.
151. Tollefson G.D., Greist J.H., Jefferson J.W., Heiligenstein J.H., Sayler M.E., Tollefson S.L., Koback K. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J. Clin. Psychopharmacol. 14:1994;385-391.
152. Upward J.W., Edwards J.G., Goldie A., Waller D.G. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br. J. Clin. Pharmacol. 26:1988;399-402.
153. Wagner W., Zaborny B.A., Gray T.E. A review of its safety profile in world-wide studies. Int. Clin. Psychopharmacol. 9:1994;223-227.
154. Wakelin J.S. Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data. Int. Clin. Psychopharmacol. 1:1986;221-230.
155. Young J.P.R., Coleman A., Lader M.H. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. Br. J. Psychiatr. 151:1987;337-340.